Lunai Bioworks
LNAI
About: Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Employees: 29
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
5.14% less ownership
Funds ownership: 13.53% [Q1] → 8.38% (-5.1%) [Q2]
29% less funds holding
Funds holding: 63 [Q1] → 45 (-18) [Q2]
56% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 32
58% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 19
65% less capital invested
Capital invested by funds: $12M [Q1] → $4.17M (-$7.79M) [Q2]
Financial journalist opinion
